Glenmede Investment Management, LP Crinetics Pharmaceuticals, Inc. Transaction History
Glenmede Investment Management, LP
- $20 Billion
- Q3 2025
A detailed history of Glenmede Investment Management, LP transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Glenmede Investment Management, LP holds 14,522 shares of CRNX stock, worth $631,997. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,522
Previous 17,134
15.24%
Holding current value
$631,997
Previous $493 Million
99.88%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding CRNX
# of Institutions
249Shares Held
92.8MCall Options Held
1.02MPut Options Held
204K-
Vanguard Group Inc Valley Forge, PA9.17MShares$399 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA8.38MShares$365 Million0.06% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.48MShares$282 Million2.29% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$271 Million0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA5.77MShares$251 Million1.04% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $2.34B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...